IBIO-610 Shows 98% Activin E Inhibition, 73% Lean Mass Preservation in Obese NHP Study
IBIO has more than doubled off its 52-week low of $0.556.
Summary
iBio reported strong preclinical data for its obesity drug candidate, IBIO-610, in obese non-human primates. A single dose achieved up to 98% inhibition of active Activin E for eight weeks. When combined with semaglutide, IBIO-610 reduced lean mass loss by 73% compared to semaglutide alone, while driving greater fat loss. This positive data for a differentiated, long-acting therapy in the high-interest obesity market follows recent progress on their IBIO-600 program and improved financials. The full dataset will be presented at the EASD Annual Meeting from September 28 – October 2.
At the time of this announcement, IBIO was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.9M. The 52-week trading range was $0.56 to $3.82. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.